From synapse to nucleus: novel targets for treating depression - PubMed (original) (raw)
Review
From synapse to nucleus: novel targets for treating depression
Herbert E Covington 3rd et al. Neuropharmacology. 2010 Mar-Apr.
Abstract
The need for newer compounds to treat depression is an ever-growing concern due to the enormous societal and financial ramifications of this disorder. Here, we review some of the candidate systems that could potentially be involved in depression, or an inherent resistance to depression termed resilience, and the numerous protein targets for these systems. A substantial body of literature provides strong evidence that neurotrophic factors, glutamate receptors, hypothalamic feeding peptides, nuclear hormone receptors, and epigenetic mechanisms, among others, will make for interesting targets when examining depressive behavior or resilience in preclinical models, and eventually clinical trials. Although some of these targets for depression already appear promising, new waves of more selective compounds for any molecular system should promote a better understanding of this complex disease and perhaps improved treatments.
Copyright 2009 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Emerging antidepressant targets from neurotrophic and glutamatergic signaling pathways. Negative modulators of downstream neurotrophic signaling acting at SPROUTY and SPRED protein families represent potential mechanisms for increasing neurotrophic function. AMPA receptor potentiators and NMDA receptor allosteric modulators (with specific subunit selectivity) are now in clinical trials. Allosteric modulators of mGluRs are also being explored in preclinical studies. Modulators of AMPA receptor expression and function, such as TARPs and CNIH, represent potential therapeutic targets as well. Compounds under development for their antidepressants effect are shown in blue boxes. New target proteins are highlighted in red boxes. CNIH, cornichon homolog; MAPK, mitogen-activated protein kinase; RTK, receptor tyrosine kinase; TARP, transmembrane AMPAR regulatory proteins; VGLUT, vesicular glutamate transporter.
Figure 2
Portrayed here is a molecular pathway analysis of genes regulated in the mouse nucleus accumbens by a direct infusion of the HDAC inhibitor MS-275 after chronic social defeat stress. Infusion of MS-275 promotes antidepressant-like behavioral responses and significantly regulates genes as revealed by microarray analysis. Examples of highly regulated molecular pathways that may provide novel targets for treating depression include genes that encode presynaptic vesicular proteins, plasma membrane receptors, intracellular signaling molecules, proteins that regulate the actin cytoskeleton, and the transcriptional regulatory machinery. Reprinted with permission from The Journal of Neuroscience (Covington et al., 2009).
Similar articles
- GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Kendell SF, Krystal JH, Sanacora G. Kendell SF, et al. Expert Opin Ther Targets. 2005 Feb;9(1):153-68. doi: 10.1517/14728222.9.1.153. Expert Opin Ther Targets. 2005. PMID: 15757488 Review. - The missing link between clinical endpoints and drug targets in depression.
Della Pasqua O, Santen GW, Danhof M. Della Pasqua O, et al. Trends Pharmacol Sci. 2010 Apr;31(4):144-52. doi: 10.1016/j.tips.2009.12.004. Epub 2010 Feb 1. Trends Pharmacol Sci. 2010. PMID: 20117847 - Reshaping the Depressed Brain: A Focus on Synaptic Health.
Gerhard DM, Ross DA. Gerhard DM, et al. Biol Psychiatry. 2018 Dec 1;84(11):e73-e75. doi: 10.1016/j.biopsych.2018.09.028. Biol Psychiatry. 2018. PMID: 30409269 Free PMC article. No abstract available. - Tryptophan hydroxylase as novel target for the treatment of depressive disorders.
Matthes S, Mosienko V, Bashammakh S, Alenina N, Bader M. Matthes S, et al. Pharmacology. 2010;85(2):95-109. doi: 10.1159/000279322. Epub 2010 Feb 3. Pharmacology. 2010. PMID: 20130443 Review. - Are compounds acting at metabotropic glutamate receptors the answer to treating depression?
Palucha A. Palucha A. Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. doi: 10.1517/13543784.15.12.1545. Expert Opin Investig Drugs. 2006. PMID: 17107280 Review.
Cited by
- SIRT1 Coordinates Transcriptional Regulation of Neural Activity and Modulates Depression-Like Behaviors in the Nucleus Accumbens.
Kim HD, Wei J, Call T, Ma X, Quintus NT, Summers AJ, Carotenuto S, Johnson R, Nguyen A, Cui Y, Park JG, Qiu S, Ferguson D. Kim HD, et al. Biol Psychiatry. 2024 Sep 15;96(6):495-505. doi: 10.1016/j.biopsych.2024.03.017. Epub 2024 Apr 3. Biol Psychiatry. 2024. PMID: 38575105 - 5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.
Villalba S, González B, Junge S, Bernardi A, González J, Fagúndez C, Torterolo P, Carrera I, Urbano FJ, Bisagno V. Villalba S, et al. Int J Mol Sci. 2024 Jan 5;25(2):687. doi: 10.3390/ijms25020687. Int J Mol Sci. 2024. PMID: 38255760 Free PMC article. - Upregulation of brain-derived neurotrophic factor by Shiikuwasha (Citrus depressa Hayata).
Nakajima K, Okubo S, Ohta T, Uto T, Oiso S. Nakajima K, et al. J Pharm Health Care Sci. 2023 Dec 12;9(1):40. doi: 10.1186/s40780-023-00309-7. J Pharm Health Care Sci. 2023. PMID: 38082356 Free PMC article. - Identification of brain areas in mice with peak neural activity across the acute and persistent phases of post-traumatic headache.
Rudolph M, Kopruszinski C, Wu C, Navratilova E, Schwedt TJ, Dodick DW, Porreca F, Anderson T. Rudolph M, et al. Cephalalgia. 2023 Nov;43(11):3331024231217469. doi: 10.1177/03331024231217469. Cephalalgia. 2023. PMID: 38016977 Free PMC article. - Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling.
Vakhitova YV, Kalinina TS, Zainullina LF, Lusta AY, Volkova AV, Kudryashov NV, Gudasheva TA, Shimshirt AA, Kadnikov IA, Voronin MV, Seredenin SB. Vakhitova YV, et al. Int J Mol Sci. 2021 Dec 13;22(24):13381. doi: 10.3390/ijms222413381. Int J Mol Sci. 2021. PMID: 34948177 Free PMC article.
References
- Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2009 in press. - PubMed
- Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry. 2001;62:332–336. - PubMed
- Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE, Jr., Witkin JM. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology. 2007;52:1482–1487. - PubMed
- Bacchi F, Mathe AA, Jimenez P, Stasi L, Arban R, Gerrard P, Caberlotto L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides. 2006;27:3202–3207. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 MH066172/MH/NIMH NIH HHS/United States
- P50 MH066172-08/MH/NIMH NIH HHS/United States
- R01 MH051399/MH/NIMH NIH HHS/United States
- R01 MH051399-18/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical